Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...
Research misconduct findings dropped sharply in 2025, prompting scrutiny of ORI leadership turnover and staffing cuts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback